美国Sage Science公司和Pacific Biosciences公司签订协议,联合营销Blue Pippin全自动核酸制备电泳系统,用于第3代基因测序的文库制备
- 环亚生物科技有限公司(APG BIO Ltd)2013年9月6日 10:15 点击:3460
环亚生物科技有限公司(APG BIO Ltd)是美国Sage Science公司在中国大陆的总代理商,详情请登录www.apgbio.com
Posted on May 16, 2013 by Alex
MENLO PARK, Calif. and BEVERLY, Mass. — May 16, 2013 — Pacific Biosciences of California, Inc., (NASDAQ:PACB), provider of the PacBio® RS II DNA Sequencing System, and Sage Science, a developer of life science products for improving sample preparation processes in molecular biology applications, today announced a co-marketing partnership to provide customers of the PacBio RS II the ability to sequence even longer DNA fragments when performing Single Molecule, Real-Time (SMRT®) Sequencing.
“We have found that the BluePippin™ size selection platform is very useful for applications where long read lengths are important, such as de novo genome assembly,” said Kevin Corcoran, Senior Vice President of Market Development at Pacific Biosciences. “Our studies have demonstrated that size selection with Sage’s BluePippin platform is an easy addition to our customers’ sample prep workflow that selects for 10 kb or larger fragments for sequencing on the PacBio RS II.”
Based on PacBio’s revolutionary SMRTSequencing technology, the PacBio RS II can generate average read lengths of 5,000 base pairs, with the longest reads above 20,000 base pairs in length. The PacBio RS II System, including consumables and software, provides a simple, fast, end-to-end workflow for SMRT Sequencing in research areas including infectious disease and microbiology, agriculture, and complex genetic diseases with repeat expansions.
The BluePippin platform, part of the Pippin line of automated size-selection tools offered by Sage Science, uses pulsed-field power to take fractions of DNA from fragments ranging from 50 bases to 50 kilobases. Independent studies of size-selection methods for next-generation sequencing sample prep have repeatedly found that the Pippin platform offers unparalleled reproducibility, accuracy, and sample recovery. By eliminating low-molecular-weight templates from sequencing libraries, automated size selection allows users to load longer fragments and boost the average read length produced by sequencing.
“This is excellent validation of the tremendous utility BluePippin offers for libraries designed to generate extraordinarily long sequence reads,” said Alex Vira, Director of Marketing for Sage Science. “We look forward to working with PacBio and its customers as they continue to deliver industry-leading read lengths and conduct countless studies that would be impossible with shorter-read technologies.”
In data presented at the Advances in Genome Biology & Technology conference earlier this year, Pacific Biosciences scientists assessed three libraries (bacterial, fish and mammalian) generated with and without BluePippin size selection. They reported that N50 subread lengths increased by 90%, 110%, and 86%, respectively, in the libraries that were size selected with BluePippin compared to those that were not.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio® RS II DNA Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, the company’s products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. More information is available at www.pacb.com.
详细信息,请联系环亚生物科技有限公司,www.apgbio.com
联系邮箱:kefu@labbase.net
版权与免责声明
- 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.labbase.net,违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
- 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。